GenomeNext makes access to its NGS patent portfolio readily available through licensing programs.

 

We license laboratories to utilize our proprietary NGS parallelization methods for human and non-human diagnostic testing, and offer companies rights to develop and commercialize NGS products that incorporate our patented parallelization technologies. 

 

GenomeNext’s out-licensing programs encompass not only the field of diagnostics but that of activities related to research, development and improvement of products and processes for human and non-human applications as well.  

 

Parallelization Methods are licensed for research, diagnostic and commercial use under U.S. Patent No. 9,552,458 and corresponding claims in its non-U.S. counterparts, owned by GenomeNext, LLC. 

 

License rights to practice patented parallelization methods under the foregoing GenomeNext patents may be obtained through (i) execution of a Services Agreement from GenomeNext, LLC, (ii) acceptance of the click-wrap license and use of GenomeNext’s Olympus Platform through www.genomenext.com, or (iii) license rights from GenomeNext, LLC.

​